Cargando…

miR-3940-5p/miR-8069 ratio in urine exosomes is a novel diagnostic biomarker for pancreatic ductal adenocarcinoma

Despite the development of several therapeutic options, the prognosis of pancreatic cancer remains poor. One reason for this is the difficulty of diagnosing the disease at an early stage. For example, carbohydrate antigen (CA) 19-9, which is the most widely used biomarker for pancreatic cancer, cann...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshizawa, Naohiko, Sugimoto, Kazushi, Tameda, Masahiko, Inagaki, Yuji, Ikejiri, Makoto, Inoue, Hiroyuki, Usui, Masanobu, Ito, Masaaki, Takei, Yoshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068395/
https://www.ncbi.nlm.nih.gov/pubmed/32218818
http://dx.doi.org/10.3892/ol.2020.11357
_version_ 1783505569810743296
author Yoshizawa, Naohiko
Sugimoto, Kazushi
Tameda, Masahiko
Inagaki, Yuji
Ikejiri, Makoto
Inoue, Hiroyuki
Usui, Masanobu
Ito, Masaaki
Takei, Yoshiyuki
author_facet Yoshizawa, Naohiko
Sugimoto, Kazushi
Tameda, Masahiko
Inagaki, Yuji
Ikejiri, Makoto
Inoue, Hiroyuki
Usui, Masanobu
Ito, Masaaki
Takei, Yoshiyuki
author_sort Yoshizawa, Naohiko
collection PubMed
description Despite the development of several therapeutic options, the prognosis of pancreatic cancer remains poor. One reason for this is the difficulty of diagnosing the disease at an early stage. For example, carbohydrate antigen (CA) 19-9, which is the most widely used biomarker for pancreatic cancer, cannot be used to detect the disease at early stages. Some studies have attempted to find novel biomarkers for pancreatic cancer. The aim of the present study was to find a novel diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC) in urine exosomes. Exosomes were isolated from urine and serum samples of patients with PDAC and control subjects, or culture media of cancer cell lines. MicroRNAs (miRNAs) were purified from exosomes. Novel biomarker candidates for PDCA were identisfied from urine exosome miRNA using expression profiling, and validated in a larger number of samples using 3D digital PCR. The results of a preliminary analysis of nine PDAC and seven control subjects revealed that the miR-3940-5p/miR-8069 ratio in urine exosomes was elevated in the patients with PDAC. Experiments using cultured cancer cell lines revealed that the elevation of the miR-3940-5p/miR-8069 ratio was specific for PDAC. Furthermore, the elevation of the miR-3940-5p/miR-8069 ratio in exosomes tended to be higher in the urine than in the serum of patients with PDAC. Validation experiments on 43 PDAC, 12 chronic pancreatitis and 25 control subjects demonstrated that the miR-3940-5p/miR-8069 ratio in urine exosomes was elevated in PDAC at a relatively early stage of the disease. When this ratio was used in combination with CA19-9 for the diagnosis of PDAC, the sensitivity and positive predictive value improved to 93.0 and 78.4%, respectively, when either of them was positive. Additionally, the positive predictive value reached 100% when both were positive. The negative predictive value also improved to 89.7% when both were negative. The miR-3940-5p/miR-8069 ratio in urine exosomes may be useful as a tool for the diagnosis of PDAC, particularly when used in combination with CA19-9.
format Online
Article
Text
id pubmed-7068395
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-70683952020-03-26 miR-3940-5p/miR-8069 ratio in urine exosomes is a novel diagnostic biomarker for pancreatic ductal adenocarcinoma Yoshizawa, Naohiko Sugimoto, Kazushi Tameda, Masahiko Inagaki, Yuji Ikejiri, Makoto Inoue, Hiroyuki Usui, Masanobu Ito, Masaaki Takei, Yoshiyuki Oncol Lett Articles Despite the development of several therapeutic options, the prognosis of pancreatic cancer remains poor. One reason for this is the difficulty of diagnosing the disease at an early stage. For example, carbohydrate antigen (CA) 19-9, which is the most widely used biomarker for pancreatic cancer, cannot be used to detect the disease at early stages. Some studies have attempted to find novel biomarkers for pancreatic cancer. The aim of the present study was to find a novel diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC) in urine exosomes. Exosomes were isolated from urine and serum samples of patients with PDAC and control subjects, or culture media of cancer cell lines. MicroRNAs (miRNAs) were purified from exosomes. Novel biomarker candidates for PDCA were identisfied from urine exosome miRNA using expression profiling, and validated in a larger number of samples using 3D digital PCR. The results of a preliminary analysis of nine PDAC and seven control subjects revealed that the miR-3940-5p/miR-8069 ratio in urine exosomes was elevated in the patients with PDAC. Experiments using cultured cancer cell lines revealed that the elevation of the miR-3940-5p/miR-8069 ratio was specific for PDAC. Furthermore, the elevation of the miR-3940-5p/miR-8069 ratio in exosomes tended to be higher in the urine than in the serum of patients with PDAC. Validation experiments on 43 PDAC, 12 chronic pancreatitis and 25 control subjects demonstrated that the miR-3940-5p/miR-8069 ratio in urine exosomes was elevated in PDAC at a relatively early stage of the disease. When this ratio was used in combination with CA19-9 for the diagnosis of PDAC, the sensitivity and positive predictive value improved to 93.0 and 78.4%, respectively, when either of them was positive. Additionally, the positive predictive value reached 100% when both were positive. The negative predictive value also improved to 89.7% when both were negative. The miR-3940-5p/miR-8069 ratio in urine exosomes may be useful as a tool for the diagnosis of PDAC, particularly when used in combination with CA19-9. D.A. Spandidos 2020-04 2020-01-29 /pmc/articles/PMC7068395/ /pubmed/32218818 http://dx.doi.org/10.3892/ol.2020.11357 Text en Copyright: © Yoshizawa et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Yoshizawa, Naohiko
Sugimoto, Kazushi
Tameda, Masahiko
Inagaki, Yuji
Ikejiri, Makoto
Inoue, Hiroyuki
Usui, Masanobu
Ito, Masaaki
Takei, Yoshiyuki
miR-3940-5p/miR-8069 ratio in urine exosomes is a novel diagnostic biomarker for pancreatic ductal adenocarcinoma
title miR-3940-5p/miR-8069 ratio in urine exosomes is a novel diagnostic biomarker for pancreatic ductal adenocarcinoma
title_full miR-3940-5p/miR-8069 ratio in urine exosomes is a novel diagnostic biomarker for pancreatic ductal adenocarcinoma
title_fullStr miR-3940-5p/miR-8069 ratio in urine exosomes is a novel diagnostic biomarker for pancreatic ductal adenocarcinoma
title_full_unstemmed miR-3940-5p/miR-8069 ratio in urine exosomes is a novel diagnostic biomarker for pancreatic ductal adenocarcinoma
title_short miR-3940-5p/miR-8069 ratio in urine exosomes is a novel diagnostic biomarker for pancreatic ductal adenocarcinoma
title_sort mir-3940-5p/mir-8069 ratio in urine exosomes is a novel diagnostic biomarker for pancreatic ductal adenocarcinoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068395/
https://www.ncbi.nlm.nih.gov/pubmed/32218818
http://dx.doi.org/10.3892/ol.2020.11357
work_keys_str_mv AT yoshizawanaohiko mir39405pmir8069ratioinurineexosomesisanoveldiagnosticbiomarkerforpancreaticductaladenocarcinoma
AT sugimotokazushi mir39405pmir8069ratioinurineexosomesisanoveldiagnosticbiomarkerforpancreaticductaladenocarcinoma
AT tamedamasahiko mir39405pmir8069ratioinurineexosomesisanoveldiagnosticbiomarkerforpancreaticductaladenocarcinoma
AT inagakiyuji mir39405pmir8069ratioinurineexosomesisanoveldiagnosticbiomarkerforpancreaticductaladenocarcinoma
AT ikejirimakoto mir39405pmir8069ratioinurineexosomesisanoveldiagnosticbiomarkerforpancreaticductaladenocarcinoma
AT inouehiroyuki mir39405pmir8069ratioinurineexosomesisanoveldiagnosticbiomarkerforpancreaticductaladenocarcinoma
AT usuimasanobu mir39405pmir8069ratioinurineexosomesisanoveldiagnosticbiomarkerforpancreaticductaladenocarcinoma
AT itomasaaki mir39405pmir8069ratioinurineexosomesisanoveldiagnosticbiomarkerforpancreaticductaladenocarcinoma
AT takeiyoshiyuki mir39405pmir8069ratioinurineexosomesisanoveldiagnosticbiomarkerforpancreaticductaladenocarcinoma